|

Intravesical Gemcitabine and Docetaxel Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 2: 1

Top Sponsors

  • Michael A. O'Donnell1

Indications

  • Micropapillary Variant Urothelial Carcinoma (Favorable Subtype)1
  • BCG-Refractory Bladder Cancer1
  • T1 Stage Bladder Cancer1
  • Ta Stage Bladder Cancer1
  • BCG-Unresponsive Bladder Cancer1

Iowa City, Iowa1 trial

Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC

University of Iowa

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.